Press releases
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
- Novocure to Report First Quarter 2024 Financial Results
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
- Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
More ▼
Key statistics
On Monday, Novocure Ltd (NVCRN:MEX) closed at 275.39, 0.00% above its 52-week low of 275.39, set on Oct 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 275.39 |
---|---|
High | 275.39 |
Low | 275.39 |
Bid | 240.00 |
Offer | 809.28 |
Previous close | 217.91 |
Average volume | 0.00 |
---|---|
Shares outstanding | 107.61m |
Free float | 97.64m |
P/E (TTM) | -- |
Market cap | 1.53bn USD |
EPS (TTM) | -1.95 USD |
Data delayed at least 20 minutes, as of Oct 02 2023 12:30 BST.
More ▼